Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-EPOCH + cART
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
R-EPOCH + cART is a combination therapy used primarily for the treatment of aggressive B-cell non-Hodgkin lymphoma in patients with HIV. The regimen consists of six drugs: rituximab (a monoclonal antibody targeting CD20 on B cells), etoposide (a topoisomerase II inhibitor), prednisone (a glucocorticoid steroid), vincristine (Oncovin; a microtubule inhibitor), cyclophosphamide (an alkylating agent), and doxorubicin (Adriamycin; an anthracycline antibiotic that intercalates DNA). The addition of cART refers to concurrent administration of combination antiretroviral therapy for HIV infection. This approach aims to treat both lymphoma and underlying HIV infection simultaneously. Each component has a distinct mechanism targeting cancer cell proliferation or survival. R-EPOCH is considered standard-of-care for certain aggressive lymphomas in people living with HIV[1][5][6][8].
- Brand names
- OncovinCytoxanAdriamycin
- Other names
- EPOCH chemotherapy regimen with rituximab and concurrent combination antiretroviral therapy
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)Gag-Pol (HIV-1 gag-pol polyprotein)TOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on R-EPOCH + cART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-EPOCH + cART.